Download
1 / 9
90 likes | 276 Vues
GBI Research, the leading business intelligence provider, has released its latest research, '‘Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs'’, which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. Detailed report at: http://www.reportsandintelligence.com/breast-cancer-therapeutics-in-major-developed-to-2020-approval-of-novel-therapies-to-support-continued-dominance-of-her2-targeted-drugs-market
E N D
Breast Cancer Therapeutics in Major Developed Markets to 2020 Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs Publisher: GBI Research No of pages: 106 Publish Date: Jan 2014
Description GBI Research, the leading business intelligence provider, has released its latest research, '‘Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs'’, which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The breast cancer therapeutics market in the eight major markets - The US, The UK, France, Germany, Spain, Italy, Japan and Canada - was worth $9.2 billion in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.1% to $13.1 billion by 2020.
Description The US had the largest market in 2013, valued at $5.5 billion, equivalent to a global share of 59%, followed by Japan with $871.5m or 9.4% and Italy with $668.5m or 7.2%. Canada had the lowest market share and value of the leading eight at 2.9% and $268.4m, but is expected to witness rapid growth over the forecast period with a CAGR of 6.7%. This will only be surpassed by Japan, which is expected to witness growth at a CAGR of 6.9%. Request for discount at: http://www.reportsandintelligence.com/purchase-enquiry/132442
Scope • Disease overview, as well as treatment algorithms and treatment usage patterns • Market size and forecast for the breast cancer market from 2012 to 2019 • Major marketed products for breast cancer along with a heat map of product performance • In-depth pipeline analysis for global pipeline in breast cancer along with clinical trial failure rate analysis • Key drivers and restraints that have had and are expected to have a significant impact upon the market • Key licensing and co-development agreements that could have impact on growth trends
Reasons to buy • Align your product portfolio to the markets with high growth potential • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer therapeutics market • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Table Of Content 1 Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 82 Breast Cancer Therapeutics in Major Developed Markets to 2020 - Introduction 92.1 Breast Cancer 92.2 Symptoms 92.3 Epidemiology 102.4 Pathophysiology 112.5 Diagnosis 112.6 Prognosis and Disease Staging 122.6.1 Classification 132.7 Treatment Options 142.7.1 Surgery and Radiation Therapy 142.7.2 Chemotherapy 142.7.3 Hormonal Therapies 15
Table Of Content 2.7.4 Targeted Therapies 152.7.5 Resistance to Pharmacological Therapies 162.7.6 Treatment Guidelines 172.7.7 Measuring the Effectiveness of Treatment 183 Breast Cancer Therapeutics in Major Developed Markets to 2020 - Marketed Products 203.1 Key Marketed Products 203.1.1 Herceptin 203.1.2 Halaven 213.1.3 Avastin 223.1.4 Gemzar 233.1.5 Taxotere 233.1.6 Tykerb 243.1.7 Femara 253.1.8 Aromasin26 3.1.9 Zoladex 263.1.10 Arimidex 27
Table Of Content 3.2 Heat Map for Marketed Products 274 Breast Cancer Therapeutics in Major Developed Markets to 2020 - Pipeline Analysis 294.1 Overall Pipeline 294.2 Pipeline Analysis by Molecule Type 314.3 Pipeline Analysis by Mechanism of Action 334.4 Clinical Trials - Failure Rate 354.5 Clinical Trial Size 374.6 Duration 394.7 Promising Drug Candidates in Pipeline 404.7.1 Buparlisib 40 Get full TOC at: http://www.reportsandintelligence.com/breast-cancer-therapeutics-in-major-developed-to-2020-approval-of-novel-therapies-to-support-continued-dominance-of-her2-targeted-drugs-market/table-of-contents
FOR MORE DETAILS Visit us at : http://www.reportsandintelligence.com/breast-cancer-therapeutics-in-major-developed-to-2020-approval-of-novel-therapies-to-support-continued-dominance-of-her2-targeted-drugs-market Stay With Us: • TELEPHONE: Direct: +1 (617) 674-4143 • Toll Free: +1 (855) 711-1555E-MAIL: sales@reportsandintelligence.com 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States
